Designing Corporate Health Check-Up Packages That Work

Most hospitals offer three tiers of package built around age bands and carried forward year after year. A panel designed for the specific workforce performs better clinically and commercially. A young workforce in a technology company, a manufacturing workforce with occupational exposures, and a largely older executive population need materially different panels, and the client can usually tell you which they are.

Design the panel around what would change management for that population, and be prepared to argue against tests the client asks for that will not. Corporate buyers often request extensive panels because more looks better in a benefits brochure. Over-testing produces incidental findings that generate anxiety and further investigation without benefit, and it inflates your cost for no clinical return. A hospital that explains this is usually respected for it and occasionally loses the contract to someone who will not.

Where an occupational health obligation applies to the client's industry, understand it before designing, because those requirements are specific and are the client's legal duty rather than a wellness benefit. Meeting them properly is a strong differentiator and getting them wrong is worse than not offering them.

Price these contracts from a full delivery cost per participant rather than from the marginal cost of the tests. The components people leave out are consistent: staff deployed on site or diverted from routine work, phlebotomy and sample logistics, the reporting and report-delivery effort at volume, clinician time for consultations and abnormal-finding review, camp logistics, and the capacity displaced in your own departments on those days.

That last item is the one that most often turns a profitable-looking contract into a loss. Two hundred corporate participants routed through your imaging department in a week displace routine work that would have been billed at ordinary rates. Unless that displacement is costed, the contract is being subsidised by the department absorbing it, and the department will notice before finance does.

Build the model per participant and state the volume assumptions on which the price depends, because volume is where these contracts move. A price quoted for six hundred participants and delivered to two hundred is a different economic proposition entirely, and without a stated assumption you have no basis to revisit it. Tiered pricing by committed volume, with a floor, protects you and is entirely ordinary commercially.

The operational design decision is whether to bring participants to the hospital or take the service to the workplace. On-site collection with hospital-based imaging is often the practical middle: it minimises disruption to the client's working day, which is what they actually care about, while keeping equipment-dependent tests where the equipment is.

Whichever model, schedule in defined slots rather than opening a window, and stage the flow so registration, sample collection, measurements and any on-site consultation form a queue that moves. Corporate participants tolerate very little waiting and their experience of your hospital that day determines whether they come back as individual patients, which is where most of the real value in these contracts sits.

Protect routine capacity explicitly. Block the corporate volume into slots that do not compete with your busiest routine periods, tell the affected departments the numbers in advance, and staff up rather than absorbing. A screening programme that makes your regular outpatients wait has traded a visible relationship for an invisible cost.

Reporting is where these programmes are judged. Participants expect their results promptly and privately, and clients expect an aggregate view of workforce health without individual detail. Both have to be built deliberately: individual reports delivered securely to the individual, and an anonymised aggregate to the employer with sufficient numbers in each category that nobody is identifiable.

That confidentiality boundary is not negotiable and should be stated in the contract and to participants at the point of screening. Employers occasionally ask for individual results, and the answer is no unless the individual has separately and genuinely consented, which is difficult to obtain meaningfully in an employment relationship. Getting this wrong damages the hospital far more than losing the contract would.

Abnormal findings need an active pathway rather than a line in a report. Significant findings should trigger a call from a clinician, not an email, with an offered appointment. This is the clinically correct handling and it is also where the programme's downstream value is realised. A screening contract with no abnormal-findings pathway is delivering results and abandoning people who need care, which is both a clinical failure and the reason the conversion assumption never materialises.

Evaluate these contracts on their full economics rather than on contract value. That means the fee received, against fully loaded delivery cost including displaced capacity, plus the value of follow-up episodes genuinely attributable to the screening. Hospitals that measure only the first two conclude the work is marginal; hospitals that measure none of them repeat it indefinitely on faith.

Attribution for the third component requires that screening participants are identifiable in your patient records and that subsequent episodes can be traced back to the programme. That is a registration and data design decision made before the camp, not an analysis performed afterwards, and it is the single thing most often omitted. Without it, the growth case for corporate contracts remains permanently unproven.

Review each contract at renewal against those figures and be willing to reprice or decline. A contract that delivers volume, disrupts capacity and produces no downstream care is not a growth channel, whatever it is called internally, and the discipline of measuring it properly is what turns corporate screening from a habit into a strategy.